Cirmtuzumab has currently completed a phase I clinical trial in patients with relapsed or refractory CLL, in which treatment with cirmtuzimab inhibited leukemia-cell activation of Rho-GPTPase and ROR1 signaling [23]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.